title: Pasireotide for the Medical Management of Feline Hypersomatotropism.
abstract: BACKGROUND
  Feline hypersomatotropism (HST) is a cause of diabetes mellitus in cats. Pasireotide is a novel multireceptor ligand somatostatin analog that improves biochemical control of humans with HST.
  
  
  OBJECTIVE
  Pasireotide improves biochemical control of HST and diabetes mellitus in cats.
  
  
  METHODS
  Hypersomatotropism was diagnosed in diabetic cats with serum insulin-like growth factor-1 (IGF-1) concentration >1,000 ng/mL by radioimmunoassay and pituitary enlargement.
  
  
  METHODS
  Insulin-like growth factor 1 was measured and glycemic control assessed using a 12-hour blood glucose curve on days 1 and 5. On days 2, 3, and 4, cats received 0.03 mg/kg pasireotide SC q12h. IGF-1, insulin dose, and estimated insulin sensitivity (product of the area under the blood glucose curve [BGC] and insulin dose) were compared pre- and post treatment. Paired t-tests or Wilcoxon signed rank tests were employed for comparison where appropriate; a linear mixed model was created to compare BGC results.
  
  
  RESULTS
  Insulin-like growth factor 1 decreased in all 12 cats that completed the study (median [range] day 1: 2,000 ng/mL [1,051-2,000] and day 5: 1,105 ng/mL [380-1,727], P = .002, Wilcoxon signed rank test). Insulin dose was lower on day 5 than on day 1 (mean reduction 1.3 [0-2.7] units/kg/injection, P = .003, paired t-test). The product of insulin dose and area under the BGC was lower on day 5 than day 1 (difference of means: 1,912; SD, 1523; u × mg/dL × hours, P = .001; paired t-test). No clinically relevant adverse effects were encountered.
  
  
  CONCLUSIONS
  Short-acting pasireotide rapidly decreased IGF-1 in cats with HST and insulin-dependent diabetes. The decrease in IGF-1 was associated with increased insulin sensitivity.
authors.affiliation: Department of Clinical Sciences and Services, Royal Veterinary College, North Mymms, UK.
authors.forename: C J
authors.initials: CJ
authors.lastname: Scudder
authors.affiliation: Department of Clinical Sciences and Services, Royal Veterinary College, North Mymms, UK.
authors.forename: R
authors.initials: R
authors.lastname: Gostelow
authors.affiliation: Department of Clinical Sciences and Services, Royal Veterinary College, North Mymms, UK.
authors.forename: Y
authors.initials: Y
authors.lastname: Forcada
authors.affiliation: Novartis Institutes for BioMedical Research, Oncology Research, Novartis Pharma AG, Basel, Switzerland.
authors.forename: H A
authors.initials: HA
authors.lastname: Schmid
authors.affiliation: Department of Clinical Sciences and Services, Royal Veterinary College, North Mymms, UK.
authors.forename: D
authors.initials: D
authors.lastname: Church
authors.affiliation: Department of Clinical Sciences and Services, Royal Veterinary College, North Mymms, UK.|Newcastle Medical School, Newcastle, Tyne and Wear, UK.
authors.forename: S J M
authors.initials: SJ
authors.lastname: Niessen
mesh_terms: D000818:Animals; D002371:Cat Diseases / Q000097:blood / Q000188:drug therapy*; D002415:Cats; D003920:Diabetes Mellitus / Q000188:drug therapy / Q000209:etiology / Q000662:veterinary; D013006:Growth Hormone / Q000031:analogs & derivatives / Q000097:blood*; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D010900:Pituitary Diseases / Q000150:complications / Q000188:drug therapy / Q000662:veterinary*; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D013004:Somatostatin; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone; C517782:pasireotide
keywords: Diabetes mellitus; Growth hormone; Inhibition; Pituitary